Corey Goodman, Ph.D., resigned as Chairman of the Board and as a director for personal reasons, effective June 29, 2026. The Board appointed Scott Garland to serve as Chairman of the Board, effective the same day. The Board also reorganized its Audit, Compensation, and Corporate Governance and Nominating committees. ALX Oncology Holdings Inc. is a biotechnology company focused on developing oncology treatments.
